Skip to main content
InsuletRevenue

Insulet Reports Third Quarter 2026 Results

Source: Autobound Signal API · 102 signals tracked for Insulet · updated

Get Insulet's live signals in Claude or ChatGPT, or by API

AskWhat changed at Insulet this week? Use Autobound signals for insulet.com.

What happened

Insulet reported third quarter 2026 revenue of $842 million, an increase of 19.2%.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency 1 ) ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its financial results for the three months ended September 30, 2026. Third Quarter Financial Highlights: Recent Strategic Highlights: Received approval from the Board of Directors for a $1 billion share repurchase program. The Company expects to allocate approximately $400 million toward repurchases in the fourth quarter of 2026, funded with existing cash. This expanded authorization reflects Insulet's strong balance sheet and disciplined approach to capital deployment. "Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion," said Ashley McEvoy, President and CEO. "We are making continued progress on our type 2 action plan, strengthening our commercial capabilities, expanding our customer base, increasing manufacturing scale and advancing innovation. As we look ahead, the business is well positioned for durable, profitable growth. The share repurchase we are announcing today demonstrates our confidence in the strength of the Omnipod platform and Insulet's long-term trajectory." 1 See description of non-GAAP financial measures contained in...

Keep reading with a free account

The rest of this article, and every signal for Insulet, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Revenue

What this signalsRevenue results often set the next budget cycle.

Amount named
$842M
Takes effect
Sep 30, 2026
Location
Acton, Massachusetts, United States

The full record

From the Signal API record

Numbers

Amount named in the story
$842M

Details

Ticker
NASDAQ:PODD

Extraction

Confidence
95%
Detected
Nov 4, 2026
signal_type
news
signal_subtype
has_revenue

Use this data

Get every revenue signal for Insulet and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Insulet this week?”

  2. Send it to your own tools

    The Signal API returns revenue signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/5d617e8c-d210-2285-7853-2d25911a19a3 returns this record as JSON. POST /v1/companies/enrich returns every signal for insulet.com.

{
  "signal_id": "5d617e8c-d210-2285-7853-2d25911a19a3",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-11-04T14:06:12+00:00",
  "company": {
    "name": "Insulet",
    "domain": "insulet.com"
  },
  "data": {
    "url": "https://www.biospace.com/press-releases/insulet-reports-third-quarter-2026-results",
    "title": "Insulet Reports Third Quarter 2026 Results - BioSpace",
    "ticker": "NASDAQ:PODD",
    "excerpt": "Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency 1 ) ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its financial results for the three months ended September 30, 2026. Third Quarter Financial Highlights: Recent Strategic Highlights: Received approval from the Board of Directors for a $1 billion share repurchase program. The Company expects to allocate approximately $400 million toward repurchases in the fourth quarter of 2026, funded with existing cash. This expanded authorization reflects Insulet’s strong balance sheet and disciplined approach to capital deployment. “Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion,” said Ashley McEvoy, President and CEO. “We are making continued progress on our type 2 action plan, strengthening our commercial capabilities, expanding our customer base, increasing manufacturing scale and advancing innovation. As we look ahead, the business is well positioned for durable, profitable growth. The share repurchase we are announcing today demonstrates our confidence in the strength of the Omnipod platform and Insulet's long-term trajectory.” 1 See description of non-GAAP financial measures contained in this...",
    "summary": "Insulet reported third quarter 2026 revenue of $842 million, an increase of 19.2%.",
    "location": "Acton, Massachusetts, United States",
    "planning": false,
    "image_url": "https://static.biospace.com/dims4/default/d32393a/2147483647/strip/true/crop/1120x630+40+0/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Fcc%2F88%2Fa9fddaf440db946b77e1d45d2e26%2Fbiospace-5.png",
    "confidence": 0.95,
    "published_at": "2026-11-04T14:06:12Z",
    "location_data": [
      {
        "city": "Acton",
        "state": "Massachusetts",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-30",
    "article_sentence": "Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency 1 ) ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its financial results for the three months ended September 30, 2026.",
    "amount_normalized": 842000000
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.